Cargando…
Prevalence of metabolic syndrome in schizophrenia patients treated with antipsychotic medications
BACKGROUND: This study was conducted to determine the prevalence of metabolic syndrome (Mets) in schizophrenic patients in a 6-month period of treatment with antipsychotic medications. METHODS: In this study, 60 volunteer schizophrenic patients were included. At the onset and 6 months after treatmen...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Babol University of Medical Sciences
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7442470/ https://www.ncbi.nlm.nih.gov/pubmed/32874439 http://dx.doi.org/10.22088/cjim.11.3.310 |
_version_ | 1783573461551022080 |
---|---|
author | Jaberi, Nayyer Faramarzi, Elnaz Farahbakhsh, Mostafa Ostadarahimi, Alireza Asghari Jafarabadi, Mohammad Fakhari, Ali |
author_facet | Jaberi, Nayyer Faramarzi, Elnaz Farahbakhsh, Mostafa Ostadarahimi, Alireza Asghari Jafarabadi, Mohammad Fakhari, Ali |
author_sort | Jaberi, Nayyer |
collection | PubMed |
description | BACKGROUND: This study was conducted to determine the prevalence of metabolic syndrome (Mets) in schizophrenic patients in a 6-month period of treatment with antipsychotic medications. METHODS: In this study, 60 volunteer schizophrenic patients were included. At the onset and 6 months after treatment with antipsychotic medications, fasting blood sugar (FBS), serum triglyceride (TG), high density lipoprotein (HDL), weight, waist circumference (WC), and blood pressure were determined. We defined Mets according to ATPIII criteria. RESULTS: After a 6-month treatment with antipsychotic drugs, the mean WC, serum TG, HDL, systolic and diastolic blood pressure increased but the changes of WC and HDL were statistically significant (p<0.05). We found that the percentage of patients with high WC, low HDL levels, and Mets increased after treatment which was statistically significant (p<0.05). CONCLUSION: It is recommended that nutritional and lifestyle changes intervention should be implanted for schizophrenic patients undergoing treatment. |
format | Online Article Text |
id | pubmed-7442470 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Babol University of Medical Sciences |
record_format | MEDLINE/PubMed |
spelling | pubmed-74424702020-08-31 Prevalence of metabolic syndrome in schizophrenia patients treated with antipsychotic medications Jaberi, Nayyer Faramarzi, Elnaz Farahbakhsh, Mostafa Ostadarahimi, Alireza Asghari Jafarabadi, Mohammad Fakhari, Ali Caspian J Intern Med Original Article BACKGROUND: This study was conducted to determine the prevalence of metabolic syndrome (Mets) in schizophrenic patients in a 6-month period of treatment with antipsychotic medications. METHODS: In this study, 60 volunteer schizophrenic patients were included. At the onset and 6 months after treatment with antipsychotic medications, fasting blood sugar (FBS), serum triglyceride (TG), high density lipoprotein (HDL), weight, waist circumference (WC), and blood pressure were determined. We defined Mets according to ATPIII criteria. RESULTS: After a 6-month treatment with antipsychotic drugs, the mean WC, serum TG, HDL, systolic and diastolic blood pressure increased but the changes of WC and HDL were statistically significant (p<0.05). We found that the percentage of patients with high WC, low HDL levels, and Mets increased after treatment which was statistically significant (p<0.05). CONCLUSION: It is recommended that nutritional and lifestyle changes intervention should be implanted for schizophrenic patients undergoing treatment. Babol University of Medical Sciences 2020-05 /pmc/articles/PMC7442470/ /pubmed/32874439 http://dx.doi.org/10.22088/cjim.11.3.310 Text en This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Jaberi, Nayyer Faramarzi, Elnaz Farahbakhsh, Mostafa Ostadarahimi, Alireza Asghari Jafarabadi, Mohammad Fakhari, Ali Prevalence of metabolic syndrome in schizophrenia patients treated with antipsychotic medications |
title | Prevalence of metabolic syndrome in schizophrenia patients treated with antipsychotic medications |
title_full | Prevalence of metabolic syndrome in schizophrenia patients treated with antipsychotic medications |
title_fullStr | Prevalence of metabolic syndrome in schizophrenia patients treated with antipsychotic medications |
title_full_unstemmed | Prevalence of metabolic syndrome in schizophrenia patients treated with antipsychotic medications |
title_short | Prevalence of metabolic syndrome in schizophrenia patients treated with antipsychotic medications |
title_sort | prevalence of metabolic syndrome in schizophrenia patients treated with antipsychotic medications |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7442470/ https://www.ncbi.nlm.nih.gov/pubmed/32874439 http://dx.doi.org/10.22088/cjim.11.3.310 |
work_keys_str_mv | AT jaberinayyer prevalenceofmetabolicsyndromeinschizophreniapatientstreatedwithantipsychoticmedications AT faramarzielnaz prevalenceofmetabolicsyndromeinschizophreniapatientstreatedwithantipsychoticmedications AT farahbakhshmostafa prevalenceofmetabolicsyndromeinschizophreniapatientstreatedwithantipsychoticmedications AT ostadarahimialireza prevalenceofmetabolicsyndromeinschizophreniapatientstreatedwithantipsychoticmedications AT asgharijafarabadimohammad prevalenceofmetabolicsyndromeinschizophreniapatientstreatedwithantipsychoticmedications AT fakhariali prevalenceofmetabolicsyndromeinschizophreniapatientstreatedwithantipsychoticmedications |